5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A consensus set of genetic vulnerabilities to ATR inhibition

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The response to DNA replication stress in eukaryotes is under the control of the ataxia–telangiectasia and Rad3-related (ATR) kinase. ATR responds to single-stranded (ss) DNA to stabilize distressed DNA replication forks, modulate DNA replication firing and prevent cells with damaged DNA or incomplete DNA replication from entering into mitosis. Furthermore, inhibitors of ATR are currently in clinical development either as monotherapies or in combination with agents that perturb DNA replication. To gain a genetic view of the cellular pathways requiring ATR kinase function, we mapped genes whose mutation causes hypersensitivity to ATR inhibitors with genome-scale CRISPR/Cas9 screens. We delineate a consensus set of 117 genes enriched in DNA replication, DNA repair and cell cycle regulators that promote survival when ATR kinase activity is suppressed. We validate 14 genes from this set and report genes not previously described to modulate response to ATR inhibitors. In particular we found that the loss of the POLE3/POLE4 proteins, which are DNA polymerase ε accessory subunits, results in marked hypersensitivity to ATR inhibition. We anticipate that this 117-gene set will be useful for the identification of genes involved in the regulation of genome integrity and the characterization of new biological processes involving ATR, and may reveal biomarkers of ATR inhibitor response in the clinic.

          Related collections

          Most cited references36

          • Record: found
          • Abstract: found
          • Article: not found

          ATR prohibits replication catastrophe by preventing global exhaustion of RPA.

          ATR, activated by replication stress, protects replication forks locally and suppresses origin firing globally. Here, we show that these functions of ATR are mechanistically coupled. Although initially stable, stalled forks in ATR-deficient cells undergo nucleus-wide breakage after unscheduled origin firing generates an excess of single-stranded DNA that exhausts the nuclear pool of RPA. Partial reduction of RPA accelerated fork breakage, and forced elevation of RPA was sufficient to delay such "replication catastrophe" even in the absence of ATR activity. Conversely, unscheduled origin firing induced breakage of stalled forks even in cells with active ATR. Thus, ATR-mediated suppression of dormant origins shields active forks against irreversible breakage via preventing exhaustion of nuclear RPA. This study elucidates how replicating genomes avoid destabilizing DNA damage. Because cancer cells commonly feature intrinsically high replication stress, this study also provides a molecular rationale for their hypersensitivity to ATR inhibitors. Copyright © 2013 Elsevier Inc. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR.

            Here we report a comprehensive biological characterization of a potent and selective small-molecule inhibitor of the DNA damage response (DDR) kinase ATR. We show a profound synthetic lethal interaction between ATR and the ATM-p53 tumor suppressor pathway in cells treated with DNA-damaging agents and establish ATR inhibition as a way to transform the outcome for patients with cancer treated with ionizing radiation or genotoxic drugs.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Fork reversal and ssDNA accumulation at stalled replication forks owing to checkpoint defects.

              Checkpoint-mediated control of replicating chromosomes is essential for preventing cancer. In yeast, Rad53 kinase protects stalled replication forks from pathological rearrangements. To characterize the mechanisms controlling fork integrity, we analyzed replication intermediates formed in response to replication blocks using electron microscopy. At the forks, wild-type cells accumulate short single-stranded regions, which likely causes checkpoint activation, whereas rad53 mutants exhibit extensive single-stranded gaps and hemi-replicated intermediates, consistent with a lagging-strand synthesis defect. Further, rad53 cells accumulate Holliday junctions through fork reversal. We speculate that, in checkpoint mutants, abnormal replication intermediates begin to form because of uncoordinated replication and are further processed by unscheduled recombination pathways, causing genome instability.
                Bookmark

                Author and article information

                Journal
                Open Biol
                Open Biol
                RSOB
                royopenbio
                Open Biology
                The Royal Society
                2046-2441
                September 2019
                11 September 2019
                11 September 2019
                : 9
                : 9
                : 190156
                Affiliations
                [1 ]Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital , 600 University Avenue, Toronto, Ontario, Canada M5G 1X5
                [2 ]Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center , Houston, TX, USA
                [3 ]Department of Molecular Genetics, University of Toronto , Toronto, Ontario, Canada M5S 1A8
                Author notes
                [†]

                Present address: Ridgeline Therapeutics,Hochbergerstrasse 60C, CH-4057 Basel, Switzerland.

                [‡]

                Present address: Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

                Electronic supplementary material is available online at https://doi.org/10.6084/m9.figshare.c.4658462.

                Author information
                http://orcid.org/0000-0003-3863-8635
                Article
                rsob190156
                10.1098/rsob.190156
                6769295
                31506018
                b0bb0534-63a3-4c63-8ab5-5038b8a64caf
                © 2019 The Authors.

                Published by the Royal Society under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, provided the original author and source are credited.

                History
                : 17 July 2019
                : 22 August 2019
                Funding
                Funded by: Canadian Institutes of Health Research, http://dx.doi.org/10.13039/501100000024;
                Award ID: FDN143343
                Funded by: European Molecular Biology Organization, http://dx.doi.org/10.13039/100004410;
                Award ID: Fellowship
                Funded by: Canadian Cancer Society Research Institute, http://dx.doi.org/10.13039/501100000015;
                Award ID: 705644
                Funded by: Cancer Prevention and Research Institute of Texas, http://dx.doi.org/10.13039/100004917;
                Award ID: RR160032
                Funded by: Canada Research Chairs, http://dx.doi.org/10.13039/501100001804;
                Award ID: Tier I Chair
                Funded by: Human Frontier Science Program, http://dx.doi.org/10.13039/501100000854;
                Award ID: Long-Term Fellowship
                Categories
                1001
                129
                181
                Research
                Research Article
                Custom metadata
                September 2019

                Life sciences
                crispr,atr,cancer therapy,dna replication,dna repair
                Life sciences
                crispr, atr, cancer therapy, dna replication, dna repair

                Comments

                Comment on this article